NBCI Search

NBCI understands the importance of clinical trials for African-Americans. It is important that African- Americans are represented in clinical trials for common diseases such as Diabetes, AIDS, cancer and heart disease that affect African Americans disproportionately.

Read our clinical trial program activities and goals.
NBCI Clinical Trials Slide Presentation

Understanding Options for Blood Cancers

  • Are you a Patient looking for Disease/Treatment Information?
  • Home Clinical Trials or Standard Treatment?
Topics Covered
  • The role of clinical trials in blood cancer treatment
  • How clinical trials are designed
  • How to determine the best treatment option for you
  • Talking to your healthcare team about treatment options

Speaker
John P. Leonard, MD
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, NY
March 18, 2015

Presentation

Q&A Session


Program Slides pdf 114kb

Transcript pdf 129kb

Leukemia and Lymphoma Society logo
Health Emergency Declaration (HED)

Clinical Trials

NBCI Seeks Newly Diagnosed Men and Women Breast Cancer Patients Who Are Members of Our Churches

Image of two women, one older, one younger and more athletic

1 Peter 5:7
4And when the chief Shepherd shall appear, ye shall receive a crown of glory that fadeth not away. 5Likewise, ye younger, submit yourselves unto the elder. Yea, all of you be subject one to another, and be clothed with humility: for God resisteth the proud, and giveth grace to the humble. 6Humble yourselves theref the mighty hand of God, that he may exalt you in due time: 7Casting all your care upon him; for he careth for you.

We would like to inform you of a study for men and women with breast cancer using Ribociclib (Kisqali™ ) and Letrozole (Femara™ ), two drugs that are already approved by the FDA (the US Food and Drug Administration). This combination of drugs is available on the market for certain breast cancer patients, but is still considered experimental for others. This study is called CompLEEment-1 (protocol number CLEE011A2404).

Study Purpose: The goal of this study is to better understand the safety and effectiveness of Ribociclib in combination with Letrozole for patients with hormone receptor positive (ER+/PR+)/HER2- advanced or metastatic breast cancer.

    Here is the population of individuals we are looking for:
  • Men, premenopausal, and postmenopausal women with a certain type of advanced breast cancer, called hormone receptor positive (ER+/PR+)/HER2- breast cancer.
  • Patients with advanced or metastatic breast cancer, which typically means that they have had to try different medications or that they were diagnosed late.
Where patients and caregivers can learn more:
To determine whether you are eligible for this study or to find a doctor's office closest to you, please contact: 1-855-413-9165 to speak with a medical information specialist.

Discuss this fact sheet with your doctor.
BREAST CANCER SITES
CHICAGO

Wendy Rogowski, PA-C
Research Coordinator
Stroger Hospital of Cook County
1900 West Polk Street, Room 449
Chicago IL 60612
312-864-5204

Thomas Lad, MD
Principal Investigator
Chairman, Division of Hematology/
Oncology Stroger Hospital of Cook County
1900 West Polk Street, Suite 755
Chicago IL 60612
312-864-7250
MIAMI/FT. LAUDERDALE

Lanetta Bronte, MD,
MPH, MSPH

President, Research Foundation
3858 Sheridan Street
Hollywood, FL 33021
Phone: (954) 397-3251

Gershwin Blyden, MD PHD
Principal Investigator
3858 Sheridan Street
Hollywood, FL 33021
Phone: (954) 397-3251

OAKLAND

Vivian Leong, RN
Clinical Research Coordinator
Sutter Alta Bates Comprehensive Cancer Center


2001 Dwight Way
Room 1314
Berkeley CA 94704
510-204-3428

Asha Damunugahakubura
Clinical Research Coordinator Alta Bates Summit
Comprehensive Cancer Center
2001 Dwight Way
Berkeley, CA 94704
(510) 204-5374

Milana Dolezal, MD MS
Principal Investigator
2001 Dwight Way
Berkeley, CA 94704
(510) 204-1591